Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans
Cost Savings Of $20m Annually Targeted; Portfolio Also Rationalized
Lannett is once again taking the axe to its operations in order to tighten its focus and save on costs, including the planned divestment of its liquids generics manufacturing facility in Carmel, New York.
You may also be interested in...
Could more Indian firms consider re-aligning their US business amid heightened pricing and compliance pressures that have cast a shadow on the long-term viability of the generics segment? A cross section of experts including a senior executive at McKinsey & Co share their views on what to expect.
Scrip delves into some of India’s critical compliance and quality challenges and efforts to address those.
Lannett is weighing major surgery for its balance sheet as it continues to feel the pain of its eye watering and unsustainable debt load.